Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd-Rüdiger Balda
Michael Hertl

Showing results (161-170 of 180) with videos related to

Pageof 18
Sort By:
The British Journal of Dermatology|December 22, 2023
Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trialNina van Beek, Rüdiger Eming, Alexander Reuss, et al.
Journal of Autoimmunity|June 3, 2015
Allelic and copy-number variations of FcγRs affect granulocyte function and susceptibility for autoimmune blistering diseasesAndreas Recke, Gestur Vidarsson, Ralf J Ludwig, et al.
Nature Communications|January 9, 2023
Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigusAnna M Sigmund, Markus Winkler, Sophia Engelmayer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 19, 2008
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseasesMichael Hertl, Detlef Zillikens, Luca Borradori, et al.
The New England Journal of Medicine|August 10, 2007
A single cycle of rituximab for the treatment of severe pemphigusPascal Joly, Hugo Mouquet, Jean-Claude Roujeau, et al.
The Journal of Investigative Dermatology|March 23, 2012
Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgarisOfer Sarig, Sivan Bercovici, Lilach Zoller, et al.
The Journal of Investigative Dermatology|September 17, 2023
Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus VulgarisDario Didona, Luca Scarsella, Christoph Hudemann, et al.
Frontiers in Medicine|June 27, 2022
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin DiseasesHideyuki Ujiie, David Rosmarin, Michael P Schön, et al.
Acta Dermato-Venereologica|June 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of PatientsAnna Pira, Martina Merli, Feliciana Mariotti, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
Pageof 18

Showing results (161-170 of 180) with videos related to

Sort By:
Pageof 18
The British Journal of Dermatology|December 22, 2023
Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trialNina van Beek, Rüdiger Eming, Alexander Reuss, et al.
Journal of Autoimmunity|June 3, 2015
Allelic and copy-number variations of FcγRs affect granulocyte function and susceptibility for autoimmune blistering diseasesAndreas Recke, Gestur Vidarsson, Ralf J Ludwig, et al.
Nature Communications|January 9, 2023
Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigusAnna M Sigmund, Markus Winkler, Sophia Engelmayer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 19, 2008
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseasesMichael Hertl, Detlef Zillikens, Luca Borradori, et al.
The New England Journal of Medicine|August 10, 2007
A single cycle of rituximab for the treatment of severe pemphigusPascal Joly, Hugo Mouquet, Jean-Claude Roujeau, et al.
The Journal of Investigative Dermatology|March 23, 2012
Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgarisOfer Sarig, Sivan Bercovici, Lilach Zoller, et al.
The Journal of Investigative Dermatology|September 17, 2023
Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus VulgarisDario Didona, Luca Scarsella, Christoph Hudemann, et al.
Frontiers in Medicine|June 27, 2022
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin DiseasesHideyuki Ujiie, David Rosmarin, Michael P Schön, et al.
Acta Dermato-Venereologica|June 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of PatientsAnna Pira, Martina Merli, Feliciana Mariotti, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
Pageof 18